<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300143</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/10/06-M</org_study_id>
    <nct_id>NCT01300143</nct_id>
  </id_info>
  <brief_title>Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma</brief_title>
  <acronym>TACERTE</acronym>
  <official_title>Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose
      total tumor mass can technically be irradiated, non-resectable, and not a candidate for
      percutaneous therapy with recommended treatment via hyperselective transarterial
      chemoembolisation (TACE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      : Phase II controlled randomized trial, multicenter, comparing the benefit of additive
      conformational radiotherapy after therapy with hyperselective chemoembolisation (TACE) with
      treatment using three TACE treatments (standard of care).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of tumor progression radiologically (CTScan) measured by mRECIST (Modified Response Evaluation Criteria In Solid Tumor).</measure>
    <time_frame>up to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the acute toxicity at the participants</measure>
    <time_frame>within 90 days after the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the late toxicity at the participants</measure>
    <time_frame>after 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the quality of life (assessed by QLQ-EORT C30)</measure>
    <time_frame>the day of randomization (week 0), at week 12 and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the rate of complete, partial response and stable disease after treatment (by RECIST criteria )</measure>
    <time_frame>at week 24,week 48 and week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the health economic implications of these regimens in these patients.</measure>
    <time_frame>up to18 months (week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>within 3 years after first cure of TACE-DC BEADS</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated by 2 or 3 cures of hyperselective TACE. The first one at week 0 and the second one at week 8. If required, a third cure of TACE could be done at week16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE + RTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated by one cure of TACE at week 0. Then, patients will be treated within two weeks by external conformational radiotherapy of 54 grey fractioned in 18 sessions during 3-4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)</description>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TACE+ RTC</intervention_name>
    <description>Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions</description>
    <arm_group_label>TACE + RTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years of age

          -  ECOG 0-1

          -  life expectancy ≥ 6 months

          -  Histologically proven hepatocellular carcinoma or proven according to radiological and
             biochemical criteria (EASL-AASLD) in cirrhotic patients

          -  Maximum lesion size ≤ 9 cm

          -  Non-eligible for surgery or percutaneous therapy

          -  Premature Child-Pugh A or B (7 points for the Child-Pugh score)

          -  AST and ALT &lt; 7 x UNL

          -  Technical possibility of conformational external radiotherapy

          -  Technical possibility of TACE

          -  All the tumor mass must be able to be treated by TACE

          -  Written consent signed by the patient

          -  Patients affiliated to a social security system

        Exclusion Criteria:

          -  Metastatic illness

          -  Minimal lesion size ≤ 5 mm

          -  Non controlled viral replication B

          -  History of radiotherapy at abdominal level

          -  Subjects capable of procreating without efficient contraception

          -  pregnancy or nursing female patient

          -  Contraindication of TACE or external conformational radiotherapy

          -  Any other concomitant experimental treatment

          -  Contraindication of Doxorubicin

          -  Patients who are unable to respect enslaving respiratory constraints if used by sites

          -  Patients who are unable to understand information and to follow protocol instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrille Feray, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital (Paris)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Lille Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy Hôpital Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Paul Brousse Villejuif</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

